| Literature DB >> 28203285 |
Guido Stirnimann1, Vanessa Banz2, Federico Storni2, Andrea De Gottardi3.
Abstract
Cirrhotic patients with refractory ascites (RA) can be treated with repeated large volume paracentesis (LVP), with the insertion of a transjugular intrahepatic portosystemic shunt (TIPS) or with liver transplantation. However, side effects and complications of these therapeutic options, as well as organ shortage, warrant the development of novel treatments. The automated low-flow ascites pump (alfapump®) is a subcutaneously-implanted novel battery-driven device that pumps ascitic fluid from the peritoneal cavity into the urinary bladder. Ascites can therefore be aspirated in a time- and volume-controlled mode and evacuated by urination. Here we review the currently available data about patient selection, efficacy and safety of the alfapump and provide recommendations for the management of patients treated with this new method.Entities:
Keywords: albumin; cirrhosis; decompensation; diuretics; spontaneous bacterial peritonitis
Year: 2017 PMID: 28203285 PMCID: PMC5298482 DOI: 10.1177/1756283X16684688
Source DB: PubMed Journal: Therap Adv Gastroenterol ISSN: 1756-283X Impact factor: 4.409